Zentalis Pharmaceuticals ... (ZNTL)
Zentalis Pharmaceuticals Statistics
Share Statistics
Zentalis Pharmaceuticals has 71.27M shares outstanding. The number of shares has increased by 0.43% in one year.
| Shares Outstanding | 71.27M |
| Shares Change (YoY) | 0.43% |
| Shares Change (QoQ) | 0.22% |
| Owned by Institutions (%) | 99.79% |
| Shares Floating | 53.59M |
| Failed to Deliver (FTD) Shares | 29.21K |
| FTD / Avg. Volume | 1.56% |
Short Selling Information
The latest short interest is 5.08M, so 7.12% of the outstanding shares have been sold short.
| Short Interest | 5.08M |
| Short % of Shares Out | 7.12% |
| Short % of Float | 9.21% |
| Short Ratio (days to cover) | 3.46 |
Valuation Ratios
The PE ratio is -3.39 and the forward PE ratio is -0.74. Zentalis Pharmaceuticals's PEG ratio is -0.49.
| PE Ratio | -3.39 |
| Forward PE | -0.74 |
| PS Ratio | 0 |
| Forward PS | 1.6 |
| PB Ratio | 2.27 |
| P/FCF Ratio | -4.75 |
| PEG Ratio | -0.49 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Zentalis Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.16, with a Debt / Equity ratio of 0.1.
| Current Ratio | 7.16 |
| Quick Ratio | 7.16 |
| Debt / Equity | 0.1 |
| Total Debt / Capitalization | 8.98 |
| Cash Flow / Debt | -4.82 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.67% and return on capital (ROIC) is -51.7%.
| Return on Equity (ROE) | -0.67% |
| Return on Assets (ROA) | -0.53% |
| Return on Capital (ROIC) | -51.7% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2,356,379.03 |
| Employee Count | 124 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -601K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -86.45% in the last 52 weeks. The beta is 1.81, so Zentalis Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.81 |
| 52-Week Price Change | -86.45% |
| 50-Day Moving Average | 2.49 |
| 200-Day Moving Average | 4.23 |
| Relative Strength Index (RSI) | 43.01 |
| Average Volume (20 Days) | 1.87M |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.39M |
| Operating Income | -248.99M |
| Net Income | -292.19M |
| EBITDA | -275.5M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -4.47 |
Balance Sheet
The company has 28.04M in cash and 43.15M in debt, giving a net cash position of -15.11M.
| Cash & Cash Equivalents | 28.04M |
| Total Debt | 43.15M |
| Net Cash | -15.11M |
| Retained Earnings | -888.56M |
| Total Assets | 450.66M |
| Working Capital | 345.39M |
Cash Flow
In the last 12 months, operating cash flow was -207.82M and capital expenditures -583K, giving a free cash flow of -208.41M.
| Operating Cash Flow | -207.82M |
| Capital Expenditures | -583K |
| Free Cash Flow | -208.41M |
| FCF Per Share | -3.19 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ZNTL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -215.94% |
| FCF Yield | -141.27% |
Analyst Forecast
The average price target for ZNTL is $8, which is 286.5% higher than the current price. The consensus rating is "Hold".
| Price Target | $8 |
| Price Target Difference | 286.5% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -2.69 |
| Piotroski F-Score | 3 |